PRTC

PureTech Health plc operates as a clinical-stage biotherapeutics company focused on discovering, developing, and commercializing treatments for devastating diseases. Headquartered in Boston, Massachusetts, and listed on the London Stock Exchange, the company was founded in 2015 and maintains a unique business model built around an internal research pipeline alongside a portfolio of Founded Entities. PureTech's wholly-owned pipeline includes late-stage programs such as LYT-100 for lymphedema and other orphan indications, deupirfenidone for idiopathic pulmonary fibrosis, and LYT-210 for obesity. The company also maintains interests in multiple Founded Entities including Karuna Therapeutics (acquired by Bristol Myers Squibb in 2024 for $14 billion), Vedanta Biosciences, Vor Biopharma, and Akili Interactive. PureTech's technology platforms span immunology, neuroscience, and inflammation, utilizing approaches that include the Brain-Immune-Gut axis, lymphatic system targeting, and oral biologic delivery systems. The company employs approximately 70 people and operates research facilities in Boston. In recent developments, PureTech advanced LYT-100 into Phase 3 trials and completed a strategic review of its Founded Entity portfolio following the successful Karuna acquisition, which generated substantial returns. The company focuses on translating scientific breakthroughs into transformative medicines while maintaining capital efficiency through its Founded Entity model.